NYSE:TAK - Takeda Pharmaceutical Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$17.15
▼ -0.05 (-0.29%)

This chart shows the closing price for TAK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Takeda Pharmaceutical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TAK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TAK

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Takeda Pharmaceutical in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $17.15.

This chart shows the closing price for TAK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 polled investment analysts is to hold stock in Takeda Pharmaceutical.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/19/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/19/2021JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
4/5/2021Jefferies Financial GroupDowngradeBuy ➝ HoldLow
3/11/2020JPMorgan Chase & Co.Lower Price TargetOverweight$31.00 ➝ $30.00Low
11/1/2019CowenInitiated CoverageMarket Perform$19.50High
9/24/2019Jefferies Financial GroupInitiated CoverageBuyLow
8/15/2019Daiwa Capital MarketsDowngradeOutperform ➝ NeutralLow
3/19/2019The Goldman Sachs GroupReiterated RatingBuyMedium
(Data available from 9/19/2016 forward)

News Sentiment Rating

-0.13 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 5 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/21/2021
  • 3 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/20/2021
  • 2 very positive mentions
  • 16 positive mentions
  • 5 negative mentions
  • 3 very negative mentions
9/19/2021

Current Sentiment

  • 2 very positive mentions
  • 16 positive mentions
  • 5 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Takeda Pharmaceutical logo
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Read More

Today's Range

Now: $17.15
Low: $17.09
High: $17.27

50 Day Range

MA: $16.79
Low: $16.30
High: $17.26

52 Week Range

Now: $17.15
Low: $15.30
High: $19.97

Volume

2,684,199 shs

Average Volume

2,709,706 shs

Market Capitalization

$54.27 billion

P/E Ratio

11.75

Dividend Yield

3.95%

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of Takeda Pharmaceutical?

The following Wall Street analysts have issued reports on Takeda Pharmaceutical in the last year: Jefferies Financial Group Inc., JPMorgan Chase & Co., and Zacks Investment Research.
View the latest analyst ratings for TAK.

What is the current price target for Takeda Pharmaceutical?

0 Wall Street analysts have set twelve-month price targets for Takeda Pharmaceutical in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Takeda Pharmaceutical in the next year.
View the latest price targets for TAK.

What is the current consensus analyst rating for Takeda Pharmaceutical?

Takeda Pharmaceutical currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TAK, but not buy more shares or sell existing shares.
View the latest ratings for TAK.

What other companies compete with Takeda Pharmaceutical?

How do I contact Takeda Pharmaceutical's investor relations team?

Takeda Pharmaceutical's physical mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The company's listed phone number is (166) 204-2111. The official website for Takeda Pharmaceutical is www.takeda.com.